Clinical trial

DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma

NCT06477211

Drugs and interventions used in this trial

0 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

No interventions are currently published for this study in CureCurrent. View the original registry record below.

Study at a glance

Registry-backed

DNA Methylation Biomarkers to Predict Survival After Surgery for Lung Adenocarcinoma

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2024-02-01

PhaseN/A

Conditions

Lung Adenocarcinomaverified · MONDO: lung adenocarcinoma

Surgeryunresolved

Prognostic Cancer Modelunresolved

Interventions

Sponsors & collaborators

Nanjing Universitylead sponsor

Peking Union Medical College Hospitalcollaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical Schoolcollaborator

Mapped research locations

NanjingJiangsu, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06477211 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.